HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

ofatumumab

HCID 178927429
New reaction
Print

Completing data — refresh the page later to see the latest

Names & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
No structure available

Names & identifiers

Preferred name
ofatumumab
English name
ofatumumab
Molecular weight
0

Names & synonyms

ofatumumabOfatumumab (anti-CD20)Research Grade OfatumumabResearch Grade Ofatumumab(DHC90701)

Database identifiers

CAS
679818-59-8

Properties

Physicochemical properties

form
Liquid
color
Colorless to light yellow
FDA UNII
95 KG522R0 · M95KG522R0
NCI Dictionary of Cancer Terms
ofatumumab
NCI Drug Dictionary
ofatumumab
ATC code
1 XC10 · L01XC10
Volume of distribution
1.7 · 1.7-5.1 Litres
Biological half-life
1.3 · 1.3-14 days (depending on number of infusions)
Hazardous Substances Data
679818 · 679818-59-8(Hazardous Substances Data)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Safety data

Hazardous Substances Data
679818-59-8(Hazardous Substances Data)

Chemistry & industry

Applications · 1 item

DescriptionConsidered as the most common form of leukemia in adults, CLL is characterized by the accumulation of abnormal B lymphocytes and manifests itself as lymph node enlargement and bone marrow failure in symptomatic patients. Ofatumumab is the second marketed mAb to target CD20. Compared to its predecessor,it is a fully human mAb that was generated via transgenic mouse and hybridoma technology. In addition to the Fab portion that recognizes CD20, the Fc domain mediates immune effector functions to lyse cells via complement-dependent cytotoxicity (CDC) and antibody-dependent, cell-mediated cytotoxicity (ADCC). Ofatumumab targets a different, discontinuous epitope on CD20 than rituximab; it binds specifically to both the small and large extracellular loops of the CD20 molecule expressed on normal B lymphocytes and on B-cell CL, and its binding does not induce receptor internalization nor shedding from the cell surface. In addition to targeting a different epitope on CD20, ofatumumab also exhibits a slower off-rate. These characteristics have been proposed as reasons for its ability to lyse rituximab-resistant cells that express low levels of CD20 and for its greater in vitro activity against CLL cells versus rituximab.The most common adverse events were neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, and upper respiratory tract infections.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes